Asset Details
Do you wish to reserve the book?
Sea Urchin Pigment Ethylspinazarin (U-573): A Novel P2X7 Receptor Antagonist with Neuroprotective and Antiparkinsonian Effects
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sea Urchin Pigment Ethylspinazarin (U-573): A Novel P2X7 Receptor Antagonist with Neuroprotective and Antiparkinsonian Effects
Do you wish to request the book?
Sea Urchin Pigment Ethylspinazarin (U-573): A Novel P2X7 Receptor Antagonist with Neuroprotective and Antiparkinsonian Effects
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sea Urchin Pigment Ethylspinazarin (U-573): A Novel P2X7 Receptor Antagonist with Neuroprotective and Antiparkinsonian Effects
2025
Overview
The ability of the quinonoid sea urchin pigment ethylspinazarin (U-573) to protect mouse Neuro-2a neuronal cells from the neurotoxic effect of one of the Parkinson’s disease inducers, MPP+, was studied. This compound blocked Ca2+ influx and inhibited macropore formation through the P2X7 receptor induced by high concentrations of ATP. Ethylspinazarin at a concentration of 10 μM increased the viability of neuronal cells treated with the neurotoxin by approximately 15% and reduced the level of NO and ROS to control values. Further, U-573 prevented the MPP+-induced formation of amyloid-like protein aggregates in neuronal cells by approximately 50%. This compound at a dosage of 1 mg/kg exerted an anti-inflammatory effect in a mouse model of inflammation, reducing ATP-induced paw edema to values of intact animals. Moreover, the potential of ethylspinazarin in providing an antiparkinsonian effect was shown using a mouse model of MPTP-induced Parkinson’s disease. It is likely that the antiparkinsonian activity in in vivo experiments may be mediated by the ability of U-573 to cross the blood–brain barrier. Finally, we found that U-573 effectively inhibits the functioning of ATP-dependent purinergic P2X7 receptors in neuronal cells. This property may be of key importance in the manifestation of the antiparkinsonian activity of this 1,4-naphthoquinone.
Publisher
MDPI AG
Subject
/ Analysis
/ Animals
/ Antiparkinson Agents - chemistry
/ Antiparkinson Agents - pharmacology
/ Cancer
/ Cell Survival - drug effects
/ Disease
/ Male
/ Mice
/ Naphthoquinones - pharmacology
/ Neurons
/ Neuroprotective Agents - chemistry
/ Neuroprotective Agents - pharmacology
/ Proteins
/ Purinergic P2X Receptor Antagonists - chemistry
/ Purinergic P2X Receptor Antagonists - pharmacology
